May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
Evaluation of the safety and efficacy of Anecortave Acetate 15 mg for Depot Suspension and triamcinolone acetate 4mg or a combination of both in patients with exudative age–related macular degeneration (AMD)
Author Affiliations & Notes
  • J.S. Slakter
    Vitreous–Retina–Macula Consultants of NY, New York, NY
  • J.A. Sorenson
    Vitreous–Retina–Macula Consultants of NY, New York, NY
  • R.F. Spaide
    Vitreous–Retina–Macula Consultants of NY, New York, NY
  • K.B. Freund
    Vitreous–Retina–Macula Consultants of NY, New York, NY
  • Footnotes
    Commercial Relationships  J.S. Slakter, Alcon Research, Ltd. C, R; J.A. Sorenson, None; R.F. Spaide, None; K.B. Freund, None.
  • Footnotes
    Support  none
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 1927. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      J.S. Slakter, J.A. Sorenson, R.F. Spaide, K.B. Freund; Evaluation of the safety and efficacy of Anecortave Acetate 15 mg for Depot Suspension and triamcinolone acetate 4mg or a combination of both in patients with exudative age–related macular degeneration (AMD) . Invest. Ophthalmol. Vis. Sci. 2004;45(13):1927.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To evaluate the safety and efficacy of combining Anecortave Acetate 15 mg Depot with intravitreal injection of triamcinolone acetate 4 mg versus using each agent alone for treatment of exudative AMD. Methods: A total of 65 patients with either 1) subfoveal occult only choroidal neovascularization (CNV) with demonstrated disease progression, or 2) subfoveal minimally classic CNV will be enrolled. The first 5 patients are treated in an open label fashion, assigned to receive both Anecortave Acetate 15mg Depot delivered by posterior juxtascleral administration and triamcinolone acetate 4mg delivered by intravitreal injection. These patients serve as a preliminary safety assessment for the combination procedure. When all 5 complete the month 3 visit, the remaining 60 patients are enrolled in a masked fashion in a 1:1:1 ratio assigned to receive either anecortave acetate 15mg with sham intravitreal injection, triamcinolone acetate 4mg delivered by intravitreal injection with sham posterior juxtascleral administration, or a combination of both. Baseline and follow–up examinations include best–corrected ETDRS visual acuity (VA), intraocular pressure assessment, optical coherence tomography (OCT–3), and fluorescein angiography (FA) for this 2 yr study. Results: The mean change from baseline in ETDRS VA for patients undergoing treatment will be shown. Additional efficacy parameters presented include percentage of patients demonstrating moderate (>3 ETDRS lines) or severe (≥6 ETDRS line) vision loss as well as effectiveness in controlling the degree of neovascular growth as demonstrated by FA. Conclusions:Given the nature of these two drugs, it is possible that a combination of the agents may provide a synergistic effect, with the strong anti–permeability effect of the steroid combined with the anti–angiogenic effect of anecortave acetate resulting in improved visual and anatomic outcomes.

Keywords: age–related macular degeneration • choroid: neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×